Germany-based Activaero has extended its collaboration agreement with TransMIT, Gesellschaft für Technologietransfer, the technology transfer agency of Justus-Liebig-University Giessen, to develop the treatment of pulmonary hypertension (PH).
As per the development collaboration, Activaero's FAVORITE (Flow and Volume Controlled Inhalation Technology) inhalation approach will be used along with an undisclosed compound to treat PH.
The program targets the affected regions of the lung with an effective dose of the inhaled drug while keeping treatment times short.
University Hospital Giessen and Marburg medical director Dr. Werner Seeger said, "We expect that through precise drug targeting on the affected lung area as well as shortened inhalation times, we will gain improved results in therapy."
